Optimization of surgical strategy for moderate ischemic mitral regurgitation: a single center prospective randomized controlled trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000036450

Enrollment

Unknown

Registered

2020-08-23

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic heart disease

Interventions

Combined group:CABG plus mitral valve repair

Isolated group:Isolated CABG

Eligibility

Sex/Gender

All

Age

20 Years to 79 Years

Inclusion criteria

Inclusion criteria: 1. Adult patients (age < 80 years); 2. Having a history of myocardial infarction or ventricular wall segmental dyskinesia indicated by echocardiography, requiring coronary artery bypass grafting; 3. Moderate IMR; 4. Normal mitral valve structure; 5. Sinus rhythm.

Exclusion criteria

Exclusion criteria: 1. Concomitant mitral valve replacement or tricuspid valve procedures; 2. Concomitant moderate or severe aortic valve diseases; 3. Echocardiography showed mitral chordae tendineae rupture and prolapse, rheumatic disease, infectious disease, valve leaf perforation, significant valve ring calcification; 4. Previous cardiac surgery, including mitral valve plasty or replacement; 5. Pregnant and lactating women; 6. Having a history of immune deficiency, malignant tumor or Marfan syndrome, Behcet's disease, Takayasu arteritis, taking hormone, etc; 7. Emergency surgeries.

Design outcomes

Primary

Measure	Time frame
LVESVI;Residual moderate or more MR;NYHA class;	—

Secondary

Measure	Time frame
Survival;Surgical death;Major postoperative morbidity;	—

Countries

China

Contacts

Public ContactJi Qiang

Zhongshan Hospital Fudan University

ji.qiang@zs-hospital.sh.cn+86 15921230800

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026